The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Statins and Stroke
Open accessAbstract
Inhibitors of HMG-CoA reductase (statins) are potent cholesterol-lowering drugs. Large clinical trials have shown that statins reduce the incidence of cerebrovascular events, which might be surprising because cholesterol is not an established risk factor for stroke. In addition to their cholesterol-lowering properties, statins exert a number of pleiotropic, vasculoprotective actions that include improvement of endothelial function, increased nitric oxide (NO) bioavailability, antioxidant properties, inhibition of inflammatory responses, immunomodulatory actions, regulation of progenitor cells, and stabilization of atherosclerotic plaques. In fact, statins augment cerebral blood flow and confer significant protection in animal models of stroke partly via mechanisms related to the upregulation of endothelial nitric oxide synthase. Retrospective clinical evidence suggests that long-term statin administration may not only reduce stroke risk but also improve outcome. Early secondary prevention trials are underway to test the hypothesis that statin treatment initiated immediately after an event improves short-term outcome. Lastly, recent evidence suggests that sudden discontinuation of statin treatment leads to a rebound effect with downregulation of NO production. Withdrawal of statin treatment may impair vascular function and increase morbidity and mortality in patients with vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · cited 2×
“Eight large, placebo-controlled and randomized studies show that statins reduce vascular events in primary and secondary prevention of coronary heart disease (4S Group, 1994; CARE Investigators, Sacks et al, 1996; LIPID Study Group, 1998; WOSCOPS Group, 1998; Byington et al, 2001; HPS Collaborative Group, 2004; Shephe…”
Background(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591 · cited 1×
“…decrease the abundance of caveolin Feron et al (2001), Pelat et al (2003) Statins promote protein kinase Akt phosphorylation and activation of eNOS Dimmeler et al (1999), Fulton et al (1999), Kureishi et al (2000) HSP90 activates eNOS; statins promote the recruitment of HSP90 to eNOS…”
BackgroundShepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499 · cited 1×
“…statin use and analysis of stroke as a predefined secondary outcome parameter in the MIRACL study showed that early treatment of patients with acute coronary syndromes reduced also the incidence of stroke (which was a predefined secondary endpoint) by 50% (Schwartz et al, 2001; Waters et al, 2002).”
BackgroundLaw, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Landmesser, U., Dikalov, S., Price, S. R., McCann, L., Fukai, T., Holland, S. M., Mitch, W. E., & Harrison, D. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200314172 · Cited by 1,660
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644 · cited 2×
“Via their structural homology to HMG-CoA (as determined by X-ray crystallography;”
Background
Cited by
Pathophysiology, treatment, and animal and cellular models of human ischemic stroke
Woodruff, T. M., Thundyil, J., Tang, S.-C., Sobey, C. G., Taylor, S. M., & Arumugam, T. V. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-11 · Cited by 598
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Kennedy, J., Hill, M. D., Ryckborst, K. J., Eliasziw, M., Demchuk, A. M., & Buchan, A. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70250-8 · Cited by 551
Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity
Romero, M. J., Platt, D. H., Tawfik, H. E., Labazi, M., El-Remessy, A. B., Bartoli, M., Caldwell, R. B., & Caldwell, R. W. (2008) · Circulation Research · doi:10.1161/circresaha.107.155028 · Cited by 386
Bench to Bedside: The Quest for Quality in Experimental Stroke Research
Dirnagl, U. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600298 · Cited by 349
Metadata
- Authors
- Endres, M.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2005-09
- Volume
- 25
- Issue
- 9
- Pages
- 1093-1110
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2092810548
- Cited by
- 200
- References
- 24
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins and Stroke. https://app.cochat.ai/papers/10.1038/sj.jcbfm.9600116
- The paper
- Endres, M. (2005). Statins and Stroke. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1038/sj.jcbfm.9600116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.